Top 20 Immunology Companies of 2024

Shots:

Immunology remains one of the most explored therapy areas. Companies focusing on immunology are steadfastly working to advance treatment options by developing drugs, vaccines, and antibodies
In 2023, the global immunology market size was valued at $98.22B and expected to register $263.22B by 2033, with a CAGR of 10.36% from 2024 to 2033. AbbVie with $26.13B reported segment revenue ranks first in our list followed by Johnson & Johnson and Sanofi
PharmaShots brings a concise report on the Top 20 Immunology Companies Based on 2023 Immunology Segment Total Revenue

S.No.	Companies	Revenue (2022) ($B)	Revenue (2023) ($B)	Percent Change (%)
1	AbbVie	28.92	26.13	9.63
2	Johnson & Johnson	16.93	18.05	6.59
3	Sanofi	10.15	14.22	40.02
4	Amgen	10.07	13.31	32.2
5	Novartis	12.31	13	5.65
6	Roche	7.55	7.64	1.25
7	AstraZeneca	5.84	6.39	9.36
8	Takeda	4.93	5.58	13.18
9	Biogen	6.17	5.40	12.57
10	Bristol-Myers Squibb	3.72	4.20	12.97
11	Eli Lilly	3.34	3.79	13.54
12	Incyte	2.87	3.09	7.72
13	Pfizer	3.33	3.02	9.24
14	UCB	2.27	2.46	8.43
15	GSK	1.38	1.71	23.85
16	Mitsubishi Tanabe Pharma	0.84	1.70	101.77
17	Astellas	1.49	1.43	3.9
18	Argenx	0.40	1.19	197.16
19	Merck & Co.	0.91	0.89	1.75
20	Organon & Co.	0.56	0.65	16.22

Note: Columns 1 and 2 represent ranks and companies, while Columns 3, 4, and 5 showcase the total immunology revenue of 2022, the total revenue of 2023, and the percentage change.

20. Organon & Co.

Immunology Segment Revenue: $0.65B

Founded Year: 2020

Market Cap: $5.56B

Total Employees: 10,000

Headquarters: New Jersey, United States

Stock Exchange: NYSE

A global healthcare company, Organon research, discovers, develops, and commercializes medicinal products for women's health
In immunology, the company develops Arcoxia (etoricoxib) and three biosimilars Hadlima (adalimumab-bwwd), Brenzys (etanercept), & Renflexis (infliximab-abda). In 2023, the immunology revenue increased by 16.22% as compared to the 2022, mainly due to the increased sales of Renflexis and Arcoxia
In Aug’23, Samsung Bioepis and Organon reported overall results of the interchangeability study of SB5 Humira biosimilar

19. Merck & Co.

Immunology Segment Revenue: $0.89B

Founded Year: 1891

Market Cap: $318.93B

Total Employees: 69,000

Headquarters: Rahway, New Jersey

Stock Exchange: NYSE

Merck offers innovative therapeutic solutions by developing and producing medicines, vaccines, biological treatments, and health products for animals and humans. The corporation splits its operations into two segments: pharmaceutical and animal health
Simponi and Remicade are the two products for autoimmune diseases under the pharmaceutical segment. In 2023, the immunology revenue of Merck decreased by 1.75% due to decreased sales of Remicade
In 2023, Aqilion announced an exclusive license and strategic research collaboration with Merck to discover, develop, and commercialize small molecule inhibitors

18. Argenx

Immunology Segment Revenue: $1.19B

Founded Year: 2008

Market Cap: $29.81B

Total Employees: ~1400

Headquarters: Amsterdam, Netherlands

Stock Exchange: EBR

Argenx is a commercial-stage biopharmaceutical company that focuses on developing and commercializing antibody-based therapies for the treatment of autoimmune diseases
Argenx's immunology segment comprises VYVGART and VYVGART Hytrulo. In 2023, immunology sales increased by 197.16% as compared to 2022 owing to increased sales of VYVGART in the United States and as well in ROW
In Nov’2023, Argenx announced the EC approval of Subcutaneous VYVGART (efgartigimod alfa and hyaluronidase-qvfc) for generalized myasthenia gravis

17. Astellas

Immunology Segment Revenue: $1.43B

Founded Year: 1923

Market Cap: $19.72B

Total Employees: ~14,500

Headquarters: Tokyo, Japan

Stock Exchange: TYO

Astellas is a multinational pharmaceutical company that focuses on genetic regulation, immuno-oncology, blindness & regeneration, and targeted protein degradation
Astellas’ only immunology product Prograf (tacrolimus) comes in different formulations, including Advagraf, Graceptor, and ASTAGRAF XL. In 2023, segment revenue dipped by 3.90% as compared to 2022 sales, owing to the lower sales of Prograf[AS2] mainly in Japan and the US
In Apr’2023, Twist Bioscience extended its collaboration with Astellas by entering into a third collaboration to support antibody discovery for Immunotherapies

16. Mitsubishi Tanabe Pharma (Mitsubishi Chemical Group)

Immunology Segment Revenue: $1.70B

Founded Year: 1993

Market Cap: $8.45B

Total Employees: ~68,600

Headquarters: Osaka, Japan

Stock Exchange: TYO

Mitsubishi Tanabe Pharma Corporation (MTPC) is the pharmaceutical division of Mitsubishi Chemical Group (MCG) that manufactures and commercializes ethical drugs
The total immunology revenue generated by autoimmune products Stelara, Simponi & Gilenya (Royalty revenue) increased the sales by 101.77% in 2023 as compared to 2022, owing to the royalty revenue of Gilenya
In Nov’23, Mitsubishi Tanabe Pharma Corporation entered into a license agreement with Kynexis for neuropsychiatric drug candidate MT-5356

15. GSK

Immunology Segment Revenue: $1.71B

Founded Year: 2000

Market Cap: $80.78B

Total Employees: ~70,200

Headquarters: London, United Kingdom

Stock Exchange: LON

GSK is a British multinational biopharma company that researches, discovers, manufactures, and commercializes therapies for infectious diseases, HIV, immunology, respiratory, and cancer
GSK's only immunology asset is Benlysta, which contributed to the total immunology sales of the company and showed an increment of 23.85% in 2023 as compared to 2022, due to strong demand for Benlysta in the US and Europe
In Feb’23, GSK’s Benlysta received an Orphan Drug Designation from the US FDA for the possible treatment of systemic sclerosis

14. UCB

Immunology Segment Revenue: $2.46B

Founded Year: 1928

Market Cap: $31.12B

Total Employees: ~9,100

Headquarters: Brussels, Belgium

Stock Exchange: EBR

A multinational biopharma company, UCB develops, manufactures, and commercializes therapies in neurology, immunology, and rare diseases
In immunology, UCB has two products Cimzia & Bimzelx. UCB reported an increase of 8.43% in the segment revenue in 2023 as compared to 2022, owing to increased sales of Bimzelx
In Oct’23, Bimzelx received the US FDA's approval for the medical care of adults with mild to severe plaque psoriasis

13. Pfizer

Immunology Segment Revenue: $3.02B

Founded Year: 1849

Market Cap: $169.88B

Total Employees: 88,000

Headquarters: New York, United States

Stock Exchange: NYSE

Pfizer is an American multinational company that develops, manufactures, and markets medicines and vaccines. The company operates in three main segments: Primary care, specialties, and oncology
Xeljanz, Enbrel, and Inflectra/Remsima are the products that fall in the immunology segment. In 2023 Pfizer’s immunology revenue decreased by 9.24% as compared to 2022, owing to the reduced sales of Xeljanz and Enbrel
In Oct’2023, the US FDA approved Pfizer’s VELSIPITY for the treatment of moderately to severely active ulcerative colitis in adult patients

12. Incyte

Immunology Segment Revenue: $3.09B

Founded Year: 2002

Market Cap: $15.02B

Total Employees: ~2300

Headquarters: Delaware, United States

Stock Exchange: NASDAQ

A global biopharmaceutical company, Incyte discovers, develops, and commercializes proprietary therapeutics. The company works in areas of Hematology/Oncology and Inflammation & Autoimmunity
Incyte’s Jakafi, Olumiant, and Jakavi (royalty revenue) are the products approved for autoimmune indications. In 2023, the company reported an increase of 7.72% in its segment revenue as compared to 2022, owing to the increased sales of Jakafi
In 2023, Incyte reported encouraging 52-week outcomes from a P-IIb trial assessing Povorcitinib (INCB54707) in individuals having extensive nonsegmental vitiligo

11. Eli Lilly & Company

Immunology Segment Revenue: $3.79B

Founded Year: 1876

Market Cap: $817.23B

Total Employees: 43,000

Headquarters: Indianapolis, United States

Stock Exchange: NYSE

Eli Lilly is an American pharmaceutical company that specializes in bone and joint disease, cancer, cardiovascular disease, diabetes, endocrine illness, immunology, neurodegeneration, neurology, and pain management
The immunology segment of Eli Lilly includes drugs like Taltz and Olumiant among others. In 2023, the immunology segment showed an incline of 13.54% in revenue as compared to 2022, due to increased sales of the above-mentioned drugs
In 2023, Eli Lilly completed the acquisition of DICE therapeutics and expanded its immunology portfolio by including oral IL-17 inhibitors

10. Bristol-Myers Squibb

Immunology Segment Revenue: $4.20B

Founded Year: 1887

Market Cap: $90.53B

Total Employees: 34,100

Headquarters: New Jersey, United States

Stock Exchange: NYSE

BMS is an American biopharma company that discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products on a global basis
The company has three autoimmune products Orencia, Sotyktu, and Zeposia. Orencia contributed the most to the total immunology revenue. The company's immunology revenue in 2023 increased by 12.97% as compared to 2022, owing to the overall increased sales of autoimmune products
In 2023, BMS and Zenas BioPharma entered into a strategic license and collaboration agreement to develop and commercialize novel bi-functional antibody Obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia

09. Biogen

Immunology Segment Revenue: $5.40M

Founded Year: 1978

Market Cap: $32.91B

Total Employees: ~8700

Headquarters: Massachusetts, United States

Stock Exchange: NASDAQ

Biogen is a biopharmaceutical company that discovers, develops, and delivers innovative treatments for Alzheimer’s, lupus, multiple sclerosis, and other therapy areas
Tysabri, Flixabi, Tecfidera, Vumerity, Avonex, Plegridy, Fampyra, Benepali, and Imraldi are the approved products of Biogen for autoimmune indications. In 2023, the immunology segment faced a decline of 12.57% as compared to 2022, due to low reported sales of Tecfidera
In 2023, the FDA approved Biogen's Tofidence (tocilizumab-bavi), a biosimilar to Actemra

08. Takeda

Immunology Segment Revenue: $5.58B

Founded Year: 1781

Market Cap: $44.19B

Total Employees: ~49,300

Headquarters: Tokyo, Japan

Stock Exchange: TYO

Takeda is a multinational pharmaceutical company that focuses on five key business areas, including Gastrointestinal, Rare diseases, PDT Immunology, Oncology, and Neuroscience
The company's PDT Immunology segment includes immunoglobulin products and Albumin products. In 2023, the segment revenue increased by 13.18% as compared to 2022, owing to the increased sales of the PDT Immunology products
In 2023, Takeda received US FDA approval to expand the use of Hyqvia to treat primary immunodeficiency in children

07. AstraZeneca

Immunology Segment Revenue: $6.39B

Founded Year: 1999

Market Cap: $236.64B

Total Employees: 89,900

Headquarters: Cambridge, United Kingdom

Stock Exchange: LON

AstraZeneca discovers, develops, and commercializes medicines in oncology, cardiovascular, renal, metabolic, respiratory, and immunology, vaccines and immune therapies, and rare diseases
Saphnelo, Soliris, and Ultomiris are AstraZeneca's immunology products. In 2023, Soliris' revenue contributed the most to the immunology segment by adding $3,145M to the revenue. In 2023, the company's immunology revenue increased by 9.36% as compared to 2022, majorly driven by the increased sales of Ultomiris
In 2023, AstraZeneca announced its intentions to acquire Gracell Biotechnologies, which was finalized in 2024. This acquisition broadened the company's focus on cancer and autoimmune diseases

06. Roche

Immunology Segment Revenue: $7.64B

Founded Year: 1896

Market Cap: $260.23B

Total Employees: 100,000

Headquarters: Basel, Switzerland

Stock Exchange: SWX

Roche is a global multinational healthcare company that discovers, develops, and commercializes therapeutic and diagnostic products. The company operates under two business segments, i.e. Pharmaceuticals and Diagnostics
Actemra/RoActemra, Xolair, and MabThera/Rituxan are the products under the immunology segment of Roche. In 2023, immunology showed a slight growth in its revenue by generating 1.25% more revenue than in 2022, due to higher sales of Actemra/RoActemra and Xolair
In 2023, Roche completed the acquisition of Telavant from Roivant, including rights to a novel TL1A-directed antibody (RVT-3101) for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease

05. Novartis

Immunology Segment Revenue: $13B

Founded Year: 1996

Market Cap: $239.30B

Total Employees: ~19,600

Headquarters: Basel, Switzerland

Stock Exchange: SWX

An innovative medicines company, Novartis discovers, develops, and sells products in cardiovascular, renal, metabolic (CRM), immunology, neuroscience, and oncology
Cosentyx, Xolair, Ilaris, Gilenya, Kesimpta, Mayzent, and Jakavi are the company's immunology products. In 2023, the total immunology revenue increased by 5.65% as compared to 2022, owing to the higher sales of immunology medicines
In 2023, the US FDA approved Novartis’ Cosentyx as the first new biologic for the treatment of hidradenitis suppurativa patients

04. Amgen

Immunology Segment Revenue: $13.31B

Founded Year: 1980

Market Cap: $180.03B

Total Employees: 26,700

Headquarters: California, United States

Stock Exchange: NASDAQ

Amgen is a global biotech company that discovers, develops, manufactures, and delivers innovative therapies. The company focuses on cardiovascular diseases, oncology, bone health, neuroscience, nephrology, and inflammation
Enbrel, Otezla, Tavneos, Tepezza, Uplizna, Prolia, Xgeva, and Amjevita are the company’s key autoimmune products. In 2023, the immunology revenue inclined 32.2% as compared to 2022, predominantly due to the overall increased sales of all the autoimmune products
In 2023, Amgen launched Amjevita the first biosimilar of Humira in the United States

03. Sanofi

Immunology Segment Revenue: $14.22B

Founded Year: 1956

Market Cap: $130.14B

Total Employees: ~86,100

Headquarters: Paris, France

Stock Exchange: NASDAQ

Sanofi is a global French pharmaceutical and healthcare company that researches, develops, manufactures, and markets pharmaceutical products in immunology and inflammation, neurology, oncology, rare blood disorders, rare diseases, and vaccines
Dupixent, Kevzara, Enjaymo, Aubagio, Thymoglobulin, and Rezurock are Sanofi's immunology products. In 2023, the segment revenue grew by 40 percent as compared to 2022 owing to increased sales of Dupixent
In 2023, Sanofi’s anti-CD40L antibody frexalimab demonstrated positive P-II results in relapsing multiple sclerosis by reducing disease activity

02. Johnson & Johnson

Immunology Segment Revenue: $18.05B

Founded Year: 1886

Market Cap: $376.12B

Total Employees: 131,900

Headquarters: New Jersey, United States

Stock Exchange: NYSE

Johnson & Johnson is a global healthcare company that provides new medications and MedTech solutions in oncology, immunology, neuroscience, cardiology, pulmonary hypertension, and ophthalmology
Remicade, Simponi/Simponi Aria, Stelara, and Tremfya among others are the company's immunology products. In 2023, the immunology segment revenue increased by 6.59% as compared to 2022, owing to the higher sales of Stelara and Tremfya
In 2023, Janssen announced encouraging topline results for JNJ-2113, an oral IL-23 receptor antagonist peptide under development for the treatment of moderate-to-severe plaque psoriasis

01. AbbVie

Immunology Segment Revenue: $26.13B

Founded Year: 2013

Market Cap: $311.16B

Total Employees: 50,000

Headquarters: Illinois, United States

Stock Exchange: NYSE

AbbVie discovers, manufactures, and commercializes products in oncology, immunology, neuroscience, eye care, aesthetics, and other chronic and complex diseases
Humira, Skyrizi, and Rinvoq are the three products in Abbvie’s immunology segment. In 2023, Abbvie faced a decline in its total immunology revenue by 9.63% as compared to 2022, owing to the lower sales of Humira
In 2023, AbbVie and Anima Biotech announced a collaboration to discover and develop mRNA biology modulators against oncology and immunology targets

Sources: